DGAP-Ad-hoc: Biotest AG / Key word(s): Offer Biotest AG: Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG 17-Sep-2021 / 12:52 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

----------------------------------------------------------------------------------------------------------------------- Ad-hoc RELEASE Announcement according to Article 17 European Market Abuse Regulation (MAR) Takeover Offer: Grifols S.A. to make a voluntary public takeover offer for the shares of Biotest AG Dreieich, 17 September 2021. Grifols S.A. announced today its decision to make a voluntary public takeover offer for all out-standing ordinary and preference shares of Biotest AG for EUR43.00 per ordinary share and EUR37.00 per preference share in an all-cash transaction. Grifols S.A. also announced that it signed a share purchase agreement with Tiancheng International Investment Limited regarding the acquisition of all shares of Tiancheng (Germany) Pharmaceutical Holdings AG, the majority shareholder of Biotest AG. For the calculation of the purchase price, the ordinary shares and the preference shares held by Tiancheng (Germany) Pharmaceutical Holdings AG were taken into account. The closing of the share purchase agreement shall be conditional on certain antitrust clearances and the publication of the decision of Grifols S.A. to launch a voluntary public takeover offer. In today's announcement, Grifols S.A. stated that Grifols S.A. does not intend, after closing of the share purchase agreement and settlement of the takeover offer, to aim for a domination and/or profit and loss transfer agreement in relation to Biotest AG in the near future.

The takeover offer shall contain several conditions to be set out in the offer document. The takeover offer shall not include a minimum acceptance threshold as condition. As it is apparent from the publication of Grifols S.A., Grifols reserves the right, to the extent legally permissible, that the final provisions and conditions of the takeover offer deviate from the framework as published today.

The Management Board and the Supervisory Board of Biotest AG will provide a statement concerning this offer pursuant to their statutory duties upon publication of the offer document.

Biotest Aktiengesellschaft Board of Management

Biotest AG Landsteinerstr. 5 D-63303 Dreieich www.biotest.com

Disclaimer This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so. About Biotest Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 1,900 employees worldwide. The preference shares of Biotest AG are listed in the Prime Standard on the Frankfurt stock exchange. IR contact Dr Monika Buttkereit phone: +49-6103-801-4406 email: investor_relations@biotest.de PR contact Dirk Neumüller phone: +49-6103-801-269 email: pr@biotest.com Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201 Preference shares: securities' ID No. 522723; ISIN DE0005227235 Listing: Frankfurt (Prime Standard) Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate Contact: Dr. Michael Ramroth Chief Financial Officer Biotest AG Landsteinerstr. 3 63303 Dreieich Tel. +40 6103 801 338 Fax: +49 6103 801 347 Michael.ramroth@biotest.com

-----------------------------------------------------------------------------------------------------------------------

17-Sep-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

----------------------------------------------------------------------------------------------------------------------- 


Language:     English 
Company:      Biotest AG 
              Landsteinerstraße 5 
              63303 Dreieich 
              Germany 
Phone:        0 61 03 - 8 01-0 
Fax:          0 61 03 - 8 01-150 
E-mail:       investor_relations@biotest.de 
Internet:     http://www.biotest.de 
ISIN:         DE0005227235, DE0005227201 
WKN:          522723, 522720 
Listed:       Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, 
              Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange 
EQS News ID:  1234247 
 
End of Announcement  DGAP News Service 
=------------

1234247 17-Sep-2021 CET/CEST

Image link: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1234247&application_name=news

(END) Dow Jones Newswires

September 17, 2021 06:52 ET (10:52 GMT)